- Home
- COP vs PFE Comparison
COP vs PFE Comparison
Compare COP & PFE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | COP | PFE |
|---|---|---|
| Founded | 1917 | 1849 |
| Country | United States | United States |
| Employees | N/A | 81000 |
| Industry | Integrated oil Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.5B | 157.2B |
| IPO Year | 2005 | 2013 |
Fundamental Metrics
Financial Performance| Metric | COP | PFE |
|---|---|---|
| Price | $113.72 | $27.65 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 20 | 11 |
| Target Price | ★ $112.95 | $27.18 |
| AVG Volume (30 Days) | 7.1M | ★ 38.6M |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | 3.04% | ★ 6.35% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.35 | 1.36 |
| Revenue | $58,944,000,000.00 | ★ $62,579,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.16 | N/A |
| P/E Ratio | $17.45 | ★ $16.46 |
| Revenue Growth | ★ 7.67 | N/A |
| 52 Week Low | $79.88 | $20.92 |
| 52 Week High | $113.80 | $27.94 |
Technical Indicators
Market Signals| Indicator | COP | PFE |
|---|---|---|
| Relative Strength Index (RSI) | 66.16 | 60.54 |
| Support Level | $90.89 | $24.99 |
| Resistance Level | $113.80 | $27.69 |
| Average True Range (ATR) | 2.59 | 0.52 |
| MACD | -0.16 | -0.04 |
| Stochastic Oscillator | 91.25 | 76.43 |
Price Performance
Historical ComparisonAbout COP ConocoPhillips
ConocoPhillips is a US-based independent exploration and production firm. Its operations are primarily in Alaska and the Lower 48, with footprints in Canada, Europe, Asia-Pacific, the Middle East, and Africa. It also has substantial integrated LNG production and marketing activities across geographies.
About PFE Pfizer Inc.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndaqel and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.